Table 2.

Study overview of SGLT transport expression in various cancers.

Author (Year), (ref #)	SGLT	Cancer Types	Study Design	Summary of findings
Ishikawa et al. (2001), [57]	SGLT-1, -2	Lung Ca.	Analyzed 96 autopsy samples with RT-PCR	Both genes expressed; levels varied between normal and cancer tissues.
Helmke et al. (2004), [58]	SGLT-1	Squamous Cell Ca.	Immunohistochemical analysis of 30 biopsy specimens	Positive staining for SGLT-1 in all samples.
Casnuf et al. (2008), [59]	SGLT-1	Pancreatic Ca.	Examined 83 pancreatic adenocarcinoma specimens	No SGLT-1 staining in normal pancreas; varied scores in cancer.
Lai et al. (2012), [60]	SGLT-1	Ovarian Ca.	Stained 178 ovarian tumor specimens	High expression in 39.7% of invasive carcinomas.
Scafooglio et al. (2015), [39]	SGLT-1, -2	Pancreatic Ca., Prostate Ca.	Mapped distribution in tumors	Both transporters expressed in adenocarcinomas, minimal staining in normal tissue.
Zhou et al. (2020), [61]	SGLT-2	Breast Ca.	Immunohistochemistry and immunoblot of 25 cases	SGLT-2 expressed in cell lines and tissue samples.
Du et al. (2022), [62]	SGLT-1, -2	Pancreatic Ca.	Study with 88 patients, specimens obtained through surgical resection	SGLT-1 overexpression predicts better prognosis than SGLT-2.
Tsunokake et al. (2023), [63]	SGLT-1, -2	Breast Ca.	Analyzed 162 cases of invasive ductal carcinoma	No significant prognostic difference between SGLT-1 and SGLT-2.